Zebra Capital Management’s Niagen Bioscience NAGE Stock Holding History

Zebra Capital Management’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-24,194	Closed	-$90K	–	182
2021 Q4	$90K	Buy	24,194 +1,174	+5%	+$6.34K	0.14%	145
2021 Q3	$144K	Hold	23,020	–	–	0.17%	162
2021 Q2	$227K	Buy	23,020 +737	+3%	+$6.43K	0.27%	127
2021 Q1	$208K	Sell	22,283 -57,544	-72%	-$456K	0.23%	148
2020 Q4	$383K	Sell	79,827 -2,963	-4%	-$14.4K	0.49%	91
2020 Q3	$332K	Buy	82,790 +56,083	+210%	+$271K	0.51%	88
2020 Q2	$123K	Sell	26,707 -623	-2%	-$2.79K	0.18%	184
2020 Q1	$89K	Sell	27,330 -1,389	-5%	-$5.33K	0.14%	186
2019 Q4	$123K	Buy	+28,719	New	+$102K	0.11%	255

Other funds holding NAGE

YRHAM

Yong Rong (HK) Asset Management Sheung Wan, Hong Kong $227M AUM 300.38% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Zebra Capital Management's NAGE Position: Q1 2022 in Review

Zebra Capital Management sold out of Niagen Bioscience (NAGE) in Q1 2022, closing a stake of 24,194 shares — an estimated $90K sold.

Zebra Capital Management first reported a position in NAGE in Q4 2019 and held it in 9 quarters. The position peaked at $383K in Q4 2020. 82 funds tracked by Wall St. Rank hold NAGE as of Q1 2022.

Zebra Capital Management reported no remaining Niagen Bioscience position as of Q1 2022 after selling out during the quarter.
Zebra Capital Management sold 24,194 Niagen Bioscience shares in Q1 2022, an estimated $90K.
Zebra Capital Management first reported a position in Niagen Bioscience in Q4 2019 and held it in 9 quarters.
Zebra Capital Management's Niagen Bioscience position peaked at $383K in Q4 2020.
82 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2022.

Based on Zebra Capital Management's 13F filing for Q1 2022, filed 16 May 2022.